According to reports, the All India Institute of Medical Sciences (AIIMS) in Delhi would begin Phase 2/3 trials of Hyderabad-based Covid-19 vaccine producer Bharat Biotech’s nasal vaccine soon.
Bharat Biotech’s intranasal vaccine got regulatory permission for second Phase trials in August, amid continuing research in several nations to produce a nasal spray to help prevent Covid-19.
According to ANI, the country’s leading hospital and research facility will begin trials in a few weeks, and an application has been filed to obtain the AIIMS Ethics Committee’s necessary approval.
Bharat Biotech’s nasal vaccine clinical trial’s principal investigator will be Dr Sanjay Rai.
After getting the ethics committee’s nod, the second phase of the trails will be conducted on volunteers who will be administered the two doses of the vaccine with a gap of four weeks in between.
The adenoviral intranasal vaccine BBV154 is the first of its kind Covid-19 vaccine to undergo human trials in India.
According to the ministry of science and technology, the Phase 1 trial in healthy volunteers of age groups ranging from 18-60 years was well tolerated. Trials for the phase 3 trials will commence after the completion of Phase-2 clinical trials.
AIIMS Delhi has also done clinical trials of Covaxin in the age group of 2 to 18 years.